Literature DB >> 26067997

Models of parent-of-origin tumorigenesis in hereditary paraganglioma.

Attje S Hoekstra1, Peter Devilee2, Jean-Pierre Bayley3.   

Abstract

Paraganglioma and pheochromocytoma are neuroendocrine tumors that originate from either the sympathetic or the parasympathetic branches of the autonomic nervous system. Although 14 different genes have been linked to paraganglioma/pheochromocytoma, a subgroup of these genes is associated with hereditary paraganglioma-pheochromocytoma, the genes related to mitochondrial succinate dehydrogenase (SDH) including SDHA, SDHB, SDHC, SDHD and the assembly factor SDHAF2. Unlike mutations in other SDH subunit genes, mutations in SDHD and SDHAF2 show a remarkable parent-of-origin dependent tumorigenesis in which tumor formation almost exclusively occurs following paternal transmission of the mutation. To date, three different models have sought to explain the striking inheritance pattern seen in SDHD and SDHAF2-linked families. Despite the fact that the models suffer to varying degrees from a lack of experimental verification, all three models have made some attempt to incorporate current data and understanding of this phenomenon. In this review, we discuss our present understanding of this phenomenon and describe the three models that seek to explain the inheritance pattern in SDHD and SDHAF2-linked families.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MAX; Paraganglioma; Pheochromocytoma; SDHAF2; SDHD

Mesh:

Substances:

Year:  2015        PMID: 26067997     DOI: 10.1016/j.semcdb.2015.05.011

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  7 in total

Review 1.  What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?

Authors:  Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 2.  Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours.

Authors:  Alfred King-Yin Lam
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

3.  Clinical progression and metachronous paragangliomas in a large cohort of SDHD germline variant carriers.

Authors:  Berdine L Heesterman; Lisa M H de Pont; Andel Gl van der Mey; Jean-Pierre Bayley; Eleonora Pm Corssmit; Frederik J Hes; Berit M Verbist; Peter Paul G van Benthem; Jeroen C Jansen
Journal:  Eur J Hum Genet       Date:  2018-05-18       Impact factor: 4.246

4.  Do the risks of Lynch syndrome-related cancers depend on the parent of origin of the mutation?

Authors:  Shimelis Dejene Gemechu; Christine M van Vliet; Aung Ko Win; Jane C Figueiredo; Loic Le Marchand; Steven Gallinger; Polly A Newcomb; John L Hopper; Noralane M Lindor; Mark A Jenkins; James G Dowty
Journal:  Fam Cancer       Date:  2020-02-27       Impact factor: 2.446

5.  A Novel MAX Gene Mutation Variant in a Patient With Multiple and "Composite" Neuroendocrine-Neuroblastic Tumors.

Authors:  Carlotta Pozza; Franz Sesti; Carla Di Dato; Emilia Sbardella; Riccardo Pofi; Francesca Schiavi; Vincenzo Bonifacio; Andrea M Isidori; Antongiulio Faggiano; Andrea Lenzi; Elisa Giannetta
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-19       Impact factor: 5.555

6.  SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas.

Authors:  Neali Armstrong; Claire M Storey; Sarah E Noll; Katherine Margulis; Myat Han Soe; Haixia Xu; Benjamin Yeh; Lauren Fishbein; Electron Kebebew; Brooke E Howitt; Richard N Zare; Julien Sage; Justin P Annes
Journal:  Cell Rep       Date:  2022-03-01       Impact factor: 9.995

7.  Mathematical modeling of disease dynamics in SDHB- and SDHD-related paraganglioma: Further step in understanding hereditary tumor differences and future therapeutic strategies.

Authors:  Dominique Barbolosi; Joakim Crona; Raphaël Serre; Karel Pacak; David Taieb
Journal:  PLoS One       Date:  2018-08-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.